The application of endoscopic assisted direct vision in transurethral columnar balloon dilation of the prostate

doi:10.3877/cma.j.issn.1674-3253.2019.03.014

Abstract

Abstract:

Objective

To explore the application value of endoscopic assisted operation in the treatment of benign prostatic hyperplasia (BPH) by transurethral columnar balloon dilation of the prostate (TUCBDP).

Methods

The clinical data of 18 patients with prostate hyperplasia who were treated with TUCBDP in the First Hospital of Shanxi Medical University from March 2018 to June 2018 were analyzed retrospectively. The international prostate symptoms score (IPSS), quality of life (QOL), maximum urinary flow rate (Qmax) and residual urine volume (RUV) were compared before and after surgery, and the operative time and complications were observed.

Results

The mean operative time of all patients was (32±10) min and the intraoperative blood loss was (19±10) ml. Compared with preoperative results, IPSS, QOL, Qmax and RUV of the patients during postoperative follow-up were significantly improved (P<0.05). One patient suffered transient incontinence after removal of the catheter, and recovered 1 week after removal. There was no true incontinence occurred.

Conclusion

Endoscopic assisted TUCBDP surgery is effective. The whole operation can be under direct vision, the catheter model and precise positioning can be accurately selected, so as to guarantee the success rate of surgery and effectively avoid the occurrence of postoperative complications such as urinary incontinence.

Key words: Columnar balloon, Prostate dilation, Benign prostatic hyperplasia, Direct vision

Weizhen Bu, Xin Wang, DongWen Wang, Zhifang Ma. The application of endoscopic assisted direct vision in transurethral columnar balloon dilation of the prostate[J]. Chinese Journal of Endourology(Electronic Edition), 2019, 13(03): 198-202.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2019.03.014

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2019/V13/I03/198

Figures/Tables 2

References 15

[1]	Nickel JC, Gilling P, Tammela TL, et al. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the enlarged prostate international comparator study (EPICS)[J]. BJU Int, 2011, 108(3): 388-394.
[2]	Roehrborn CG. Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations[J]. Reviews in urology, 2008, 10(1): 14-25.
[3]	Reich O, Gratzke C, Bachmann A, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients[J]. J Urol, 2008, 180(1): 246-249.
[4]	Huang W, Guo Y, Xiao G, et al. Treatment of benign prostatic hyperplasia using transurethral split of the prostate with a columnar balloon catheter[J]. J Endourol, 2015, 29(3): 344-350.
[5]	李仁彪，赵峰，贺彦君, 等. 前列腺突入膀胱内距离对经尿道柱状水囊前列腺扩开术疗效的影响[J].中国药物与临床, 2017, 17(5): 636-639.
[6]	刘泽涛，于莉，张启波, 等. 经尿道前列腺电切术和等离子电切术治疗前列腺增生的比较[J/CD]. 中华腔镜泌尿外科杂志(电子版), 2017, 11(5): 322-325.
[7]	吕磊，黄韬，高晓玲, 等. 超选择性前列腺动脉栓塞联合经尿道前列腺切除治疗重度前列腺增生的疗效[J]. 中华泌尿外科杂志, 2018, 39(9): 675-678.
[8]	那彦群. 中国泌尿外科疾病诊断治疗指南[M]. 人民卫生出版社, 2013.
[9]	郭应禄. 经尿道柱状水囊前列腺扩开术[M]. 北京: 北京大学医学出版社, 2015.
[10]	张勇，张志超，田龙, 等. 复合球囊前列腺扩张术治疗前列腺增生的实验研究[J]. 现代泌尿外科杂志, 2009, 14(3): 218-221.
[11]	Chang Y, Chang J, Wang H. Transurethral balloon dilatation of the prostate and transurethral plasmakinetic resection of the prostate in the treatment of prostatic hyperplasia[J]. Pak J Med Sci, 2018, 34(3): 736-739.
[12]	Huang WG, Huang Z, Xiao G, et al. Effect of transurethral split of the prostate using a idouble-columnar balloon catheter for benign prostatic hyperplasia: A single-center experience of 565 consecutive patients[J]. Medicine (Baltimore), 2016, 95(40): e4657.
[13]	侯淑均，刘红珍，高博, 等. 经尿道柱状水囊前列腺扩开术与经尿道前列腺电切术的对比研究[J]. 中华全科医学, 2017, 15(3): 542-544.
[14]	王充，苗晓林，连文峰, 等. 超声引导下经尿道柱状水囊前列腺扩开术治疗前列腺增生[J]. 微创泌尿外科杂志, 2018, 7(4): 263-266.
[15]	刁英智，任向宏，张明华, 等. 超声引导下经尿道前列腺水囊扩开术治疗良性前列腺增生的1年疗效分析[J]. 中华泌尿外科杂志, 2014, 35(6): 457-460.

项目	IPSS（分）	QOL（分）	Qmax（ml/s）	RUV（ml）
术前	27.4±6.0	5.4±0.8	05.8±1.6	86±96
术后3个月	12.1±3.1	2.0±0.9	14.5±1.9	12±11
t值	16.318	19.606	-20.191	4.536
P值	<0.001	<0.001	<0.001	<0.001

项目	IPSS（分）	QOL（分）	Qmax（ml/s）	RUV（ml）
术前	27.4±6.0	5.4±0.8	05.8±1.6	86±96
术后3个月	12.1±3.1	2.0±0.9	14.5±1.9	12±11
t值	16.318	19.606	-20.191	4.536
P值	<0.001	<0.001	<0.001	<0.001

Please choose a citation manager

Content to export